Abstract
The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Volume: 11 Issue: 3
Author(s): Sarmad Said and German T. Hernandez
Affiliation:
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Abstract: The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.
Export Options
About this article
Cite this article as:
Said Sarmad and Hernandez T. German, Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/187152571103140120103032
DOI https://dx.doi.org/10.2174/187152571103140120103032 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus
Current Pharmaceutical Design Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease
Protein & Peptide Letters Mitochondrial Dysfunction during Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Review and Research on Feature Selection Methods from NMR Data in Biological Fluids. Presentation of an Original Ensemble Method Applied to Atherosclerosis Field
Current Drug Metabolism Considerations in the Pharmacotherapy of Bipolar Disorder During and After Pregnancy
Current Drug Safety Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints
Current Pharmaceutical Design The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Disturbed Homeostasis in Patients with Acute Psychosis
Current Psychiatry Reviews Effects of Insulin on the Vasculature
Current Vascular Pharmacology Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry EHDA Spraying: A Multi-Material Nano-Engineering Route
Current Pharmaceutical Design New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets In Utero Exposure to Phthalates and Fetal Development
Current Medicinal Chemistry